OncoMatch/Clinical Trials/NCT05136846
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
Is NCT05136846 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for locally advanced lung non-small cell carcinoma.
Treatment: Carboplatin · Durvalumab · Paclitaxel · Papaverine · Pemetrexed — This phase I trial finds out the best dose, possible benefits and/or side effects of papaverine when given together with chemoradiation intreating patients with stage II-III non-small cell lung cancer. Papaverine targets mitochondrial metabolism to decrease the cancer growth process. Giving papaverine with chemoradiation may work best to treat patients with non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage II, IIA, IIB, III, IIIA, IIIB, IIIC
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Exception: No prior radiation therapy which would result in overlapping radiation fields
History of previous radiation therapy which would result in overlapping radiation fields
Cannot have received: nitrates or nitroglycerin
Patients who are presently receiving nitrates or nitroglycerin, or have received these medications within 30 days of day 1 of protocol treatment
Cannot have received: Sildenafil (Sildenafil)
Exception: Must discontinue use for 2 days prior to initiation of papaverine, during the duration of study, and for 2 days after last dose of papaverine
Patients who are currently taking Sildenafil should agree to discontinue use for 2 days prior to initiation of papaverine, during the duration of study, and for 2 days after last dose of papaverine
Lab requirements
Blood counts
Absolute neutrophil count >=1.5 x 10^9/L; Hemoglobin >= 9 g/dL; Platelets >= 100 x 10^9/L
Kidney function
Creatinine < 1.5 mg/dL or calculated creatinine clearance >= 50 mL/min or 24-hour urine creatinine clearance >= 50 mL/min
Liver function
Total bilirubin <= 1.5 x ULN; AST and ALT <= 2.5 x ULN
Absolute neutrophil count >=1.5 x 10^9/L; Hemoglobin >= 9 g/dL; Platelets >= 100 x 10^9/L; Total bilirubin <= 1.5 x ULN; AST and ALT <= 2.5 x ULN; Creatinine < 1.5 mg/dL or calculated creatinine clearance >= 50 mL/min or 24-hour urine creatinine clearance >= 50 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05136846 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, nitrates or nitroglycerin, Sildenafil disqualifies patients from enrollment.
What disease stage is eligible?
Stage II or IIA or IIB or III or IIIA or IIIB or IIIC is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages